Draft:Gimantan
| Submission declined on 11 December 2024 by Reba16 (talk). Thank you for your submission, but the subject of this article already exists in Wikipedia. You can find it and improve it at Hemantane instead.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
 | |
| Clinical data | |
|---|---|
| Other names | Hemantane, Himantane, A-7. |
| Identifiers | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C16H27N |
| Molar mass | 233.399 g·mol−1 |
| 3D model (JSmol) | |
| |
Gimantan (Hemantane) is a Russian monoamine oxidase inhibitor. It has an adamantane amine molecular structure and is similar to related agents such as amantadine and memantine.
It is patented for the treatment of pain and inflammation,[1] alcoholism:[2] Cerebral circulation:[3] and Parkinson’s disease.[4]
The dosage is standardized to 50mg Tablets:[5]
Synthesis
[edit]Gimantan is synthesized, according to the Leuckart reaction, by heating adamantan-2-one and hexamethyleneimine in the presence of formic acid.[6][7][8]
References
[edit]- ^ Елена Артуровна Вальдман, RU2559777C2 (2014).
- ^ RU2582966C2
- ^ RU2554502C2
- ^ RU2423981C2
- ^ Tsvetkova EA, Volkova MY, Stepanenko OB, Kislyak NA, Shcherbakova OV, Avdyunina NI, et al. (January 2002). "Gimantan Tablets: Analysis and Standardization". Pharmaceutical Chemistry Journal. 36 (1): 48–50. doi:10.1023/A:1015761110991.
- ^ Sergeeva MS, Grushevskaya LN, Pyatin BM, Avdyunina NI, Gaevaya LM, Klumova VS, et al. (November 2011). "Pharmaceutical analysis and standardization of gimantan parenteral dosage form". Pharmaceutical Chemistry Journal. 45 (8): 499–502. doi:10.1007/s11094-011-0664-1.
- ^ Seredenin SB, Voronina TA, Avdyunina NI, Pyatin BM, Morozov IS, Bykov NP, et al. (2010). "SU1825499 "N-(2-adamantyl)hexamethyleneimine hydrochloride with anticataleptic activity". Byull. Izobret. (in Russian). 4.
- ^ Tsvetkova EA, Volkova MY, Stepanenko OB, Avdyunina NI, Bol'shakova RF, Pyatin BM (November 2001). "Analysis and Standardization of the New Domestic Antiparkinsonian Drug Gimantan". Pharmaceutical Chemistry Journal. 35 (11): 635–638. doi:10.1023/A:1015158213734.
Category:Adamantanes
Category:Amines
Category:Antidementia agents
Category:Antiparkinsonian agents